Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of NT 201 in Japanese patients with blepharospasm
jRCT2031230711Phase 3Completed
- Sponsor
- Teijin Pharma
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in idiopathic blepharospasm (BEB), sponsored by Teijin Pharma. Primary endpoint: Change from baseline in JRS severity score at 6 weeks after the first injection. Started Apr 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
idiopathic blepharospasm (BEB)
Beyond the preview
Go deeper on jRCT2031230711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230711.